CO2022009691A2 - Formulaciones líquidas de tasimelteón y métodos para su uso - Google Patents

Formulaciones líquidas de tasimelteón y métodos para su uso

Info

Publication number
CO2022009691A2
CO2022009691A2 CONC2022/0009691A CO2022009691A CO2022009691A2 CO 2022009691 A2 CO2022009691 A2 CO 2022009691A2 CO 2022009691 A CO2022009691 A CO 2022009691A CO 2022009691 A2 CO2022009691 A2 CO 2022009691A2
Authority
CO
Colombia
Prior art keywords
tasimelteon
methods
liquid formulations
liquid
formulations
Prior art date
Application number
CONC2022/0009691A
Other languages
English (en)
Spanish (es)
Inventor
Deepak Phadke
Mihael Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73856392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2022009691(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CO2022009691A2 publication Critical patent/CO2022009691A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CONC2022/0009691A 2019-12-13 2022-07-11 Formulaciones líquidas de tasimelteón y métodos para su uso CO2022009691A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962947774P 2019-12-13 2019-12-13
US202062972902P 2020-02-11 2020-02-11
US202063119488P 2020-11-30 2020-11-30
PCT/US2020/064555 WO2021119456A1 (en) 2019-12-13 2020-12-11 Liquid tasimelteon formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2022009691A2 true CO2022009691A2 (es) 2022-07-29

Family

ID=73856392

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0009691A CO2022009691A2 (es) 2019-12-13 2022-07-11 Formulaciones líquidas de tasimelteón y métodos para su uso

Country Status (14)

Country Link
US (5) US11202770B2 (cg-RX-API-DMAC7.html)
EP (1) EP4072542A1 (cg-RX-API-DMAC7.html)
JP (3) JP7503632B2 (cg-RX-API-DMAC7.html)
KR (1) KR102650321B1 (cg-RX-API-DMAC7.html)
CN (1) CN114727978A (cg-RX-API-DMAC7.html)
AU (3) AU2020400065B2 (cg-RX-API-DMAC7.html)
CA (1) CA3161975A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001546A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009691A2 (cg-RX-API-DMAC7.html)
IL (2) IL292492A (cg-RX-API-DMAC7.html)
MX (2) MX2022006577A (cg-RX-API-DMAC7.html)
NZ (1) NZ811397A (cg-RX-API-DMAC7.html)
WO (1) WO2021119456A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207188B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof
AU2022345260A1 (en) 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients
WO2024258786A1 (en) 2023-06-12 2024-12-19 Vanda Pharmaceuticals Inc. Tasimelteon for use in the treatment of delayed sleep-wake phase disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499106B1 (ko) * 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
WO2011112167A1 (en) * 2009-03-13 2011-09-15 Reset Therapeutics, Inc. Compositions and methods for diabetes treatment
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
CN102675268A (zh) 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备(1r,2r)-2-(2,3-二氢苯并呋喃-4-基)环丙甲胺的方法
IL266159B2 (en) 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6921534B2 (ja) 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 高純度医薬品等級タシメルテオン
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
CN106542973B (zh) * 2015-09-16 2019-06-25 南京华威医药科技集团有限公司 他司美琼中间体及其制备方法
WO2017059877A1 (en) 2015-10-07 2017-04-13 Rontis Hellas S.A. Pharmaceutical composition containing agomelatine and process for the preparation thereof
US9944616B2 (en) * 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
US12447141B2 (en) 2025-10-21
JP2024084859A (ja) 2024-06-25
US20260007633A1 (en) 2026-01-08
US11759446B2 (en) 2023-09-19
JP7503632B2 (ja) 2024-06-20
US11202770B2 (en) 2021-12-21
MX2026003536A (es) 2026-05-04
US20210177799A1 (en) 2021-06-17
CL2022001546A1 (es) 2023-02-24
MX2022006577A (es) 2022-07-04
NZ811397A (en) 2025-11-28
US20250090492A1 (en) 2025-03-20
AU2026202446A1 (en) 2026-04-23
CN114727978A (zh) 2022-07-08
JP2026117039A (ja) 2026-07-14
JP7875899B2 (ja) 2026-06-18
AU2025205489B2 (en) 2026-01-29
KR102650321B1 (ko) 2024-03-21
US12440470B2 (en) 2025-10-14
WO2021119456A1 (en) 2021-06-17
AU2025205489A1 (en) 2025-08-14
AU2020400065B2 (en) 2025-08-14
EP4072542A1 (en) 2022-10-19
JP2023506225A (ja) 2023-02-15
US20210212980A1 (en) 2021-07-15
AU2020400065A1 (en) 2022-06-30
IL292492A (en) 2022-06-01
NZ811345A (en) 2025-07-25
KR20220113983A (ko) 2022-08-17
ZA202207188B (en) 2022-08-31
US20230372285A1 (en) 2023-11-23
IL317244A (en) 2025-01-01
NZ789270A (en) 2024-07-05
CA3161975A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2022001546A1 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
MX2019003406A (es) Estructuras de nonofibra y metodos de uso de las mismas.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
CR20160314A (es) Anticuerpos anti-cd3 y metodos de uso
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso